NCT00061919View on ClinicalTrials.gov

Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

724

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

February 28, 2007

Study Completion Date

July 31, 2007

Conditions
Lung Cancer
Interventions
DRUG

Carboplatin, etoposide & thalidomide

Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.

DRUG

Carboplatin, etoposide & placebo

Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.

Trial Locations (1)

WIT 3AA

University College of London Hospitals, London

All Listed Sponsors
lead

University College, London

OTHER

NCT00061919 - Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter